AX-2026-041429 · Retatrutide · QYB lot QYB-2604-B4920

Section 1

Results

Measured against the index acceptance specification for the incretin analogues and co-agonists class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 25 min gradient, 214 nm	98.53	% area	≥ 96.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	1.47	% area	≤ 3.5	PASS
Largest single impurity	RP-HPLC — oxidised Trp (+16 Da)	0.81	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	4728.4871	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, unit resolution (single quadrupole)	4728.4966	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	+2.0	ppm	± 15	PASS
Total peptide content	by difference from the gravimetric mass balance	88.04	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	86.75	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	13.81	mg	12 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	11.980	mg	12 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	99.8	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	2.69	%	≤ 8.0	PASS
Counter-ion (TFA)	anion-exchange ion chromatography	8.97	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.30	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	membrane filtration, USP <71>, 14 d	No growth at 14 d	—	no growth	PASS
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	3.78	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 25 min gradient	17.50	min	17.53 ± 0.50 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.57	—	0.80 – 1.50	FAIL
Plate count, main peak	N = 5.54 (t/w½)²	60,645	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Aib2]-diastereomer	0.63	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 25 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 60,645, and skew follows the reported asymmetry factor of 1.57. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.81 % impurity against a 98.53 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Retatrutide — main peak	17.50	4,788,863	98.53	—
2	oxidised Trp (+16 Da)	16.95	39,369	0.81	+15.995
3	des-Aib20 analogue	17.13	19,927	0.41	-85.053
4	[D-Aib2]-diastereomer	17.32	7,290	0.15	0.000
5	C18 diacid regioisomer	17.98	2,916	0.06	0.000
6	aspartimide (−18 Da)	18.09	1,458	0.03	-18.011
7	incomplete Fmoc removal (+222 Da)	19.51	486	0.01	+222.068
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 4728.4871 Da, computed from C221H342N46O68. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, unit-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 4728.4966 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
7+	676.5054	676.5068	0.0014	7.9
6+	789.0885	789.0900	0.0015	51.7
5+	946.7047	946.7066	0.0019	100.0
4+	1183.1291	1183.1314	0.0023	52.7
3+	1577.1696	1577.1728	0.0032	8.2

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	2.69
Counter-ion (TFA)	ion chromatography	8.97
Residual solvent + inorganic residue	estimated	0.30
Total peptide content	by difference	88.04
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.19	98.53	divergence -0.31 pp vs batch median
Total impurities (% area)	not stated	1.47
Largest single impurity (% area)	not stated	0.81
Water (%)	0.4	2.69
Counter-ion (%)	not stated	8.97
Peptide content (%w/w)	not stated	88.04
Endotoxin (EU/mg)	0.46	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → third-party forwarder (2 d) → laboratory (courier, cold pack, 9 d) → assay.
Assay date: 21 Aug 2026
Submitted to the index: 08 Sep 2026
Laboratory: Medutest, Ljubljana, Slovenia
Method basis: 25 min gradient · unit-resolution MS
Verification status: IDENTITY CONSISTENT

What this report does not establish

That the compound is not a near-isobaric alternative. Identity was confirmed at unit mass resolution, which cannot exclude species differing by 1 or 2 Da. The specific alternatives not excluded are named in the identity block above.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 2

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

tbu_residual08 Sep 2026

No +56 Da satellite in the envelope, which is the residual-protection signature. Its absence is worth as much as the parent mass being right.

price_per_mg08 Sep 2026

A retail purchase carries a price, which makes cost per milligram of recovered peptide computable. That is the comparison a buyer actually needs and it exists only for this provenance class.

Section 7

Related records

Same batch — lot QYB-2604-B4920 n=10

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041426	QYB-2604-B4920	Janoshik	2026-Q3	98.25	2.04	91.7	Buyer-sourced	0	PASS
AX-2026-041427	QYB-2604-B4920	PeptideMeter	2026-Q3	97.93	2.45	101.7	Buyer-sourced	0	PASS
AX-2026-041428	QYB-2604-B4920	Janoshik	2026-Q3	98.35	3.20	—	Laboratory-retained	0	PASS
AX-2026-041430	QYB-2604-B4920	Kestrel	2026-Q3	99.52	2.89	—	Buyer-sourced	1	FAIL
AX-2026-041431	QYB-2604-B4920	Janoshik	2026-Q3	98.63	2.32	94.2	Buyer-sourced	0	PASS
AX-2026-041432	QYB-2604-B4920	Janoshik	2026-Q3	98.46	2.14	93.3	Buyer-sourced	0	PASS
AX-2026-041433	QYB-2604-B4920	Janoshik	2026-Q3	98.55	2.57	97.1	Buyer-sourced	0	PASS
AX-2026-041434	QYB-2604-B4920	Medutest	2026-Q3	99.02	2.65	96.9	Laboratory-retained	0	PASS
AX-2026-041435	QYB-2604-B4920	Janoshik	2026-Q3	98.34	2.53	—	Buyer-sourced	0	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Retatrutide records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-042437	Homopeptide	HOMO-2605-V4718	Nordanalyt	2026-Q3	98.68	3.67	102.8	Buyer-sourced	PASS
AX-2026-043095	KP	KP-2607-H5774	Janoshik	2026-Q3	95.81	5.48	105.2	Buyer-sourced	FAIL
AX-2026-042282	TFC	TFC-2608-J1156	Janoshik	2026-Q3	98.54	4.27	—	Buyer-sourced	PASS
AX-2026-043094	KP	KP-2607-H5774	PeptideMeter	2026-Q3	96.32	6.40	—	Buyer-sourced	FAIL
AX-2026-042441	Homopeptide	HOMO-2605-V4718	Medutest	2026-Q3	98.93	4.22	—	Buyer-sourced	PASS
AX-2026-041427	QYB	QYB-2604-B4920	PeptideMeter	2026-Q3	97.93	2.45	101.7	Buyer-sourced	PASS
AX-2026-041786	ASY	ASY-{CAT}-2288	VendorInvestigate	2026-Q3	98.78	6.59	—	Buyer-sourced	PASS
AX-2026-041428	QYB	QYB-2604-B4920	Janoshik	2026-Q3	98.35	3.20	—	Laboratory-retained	PASS

Other recent QYB records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-041471	PT-141 (Bremelanotide)	QYB-2607-L4875	Janoshik	2026-Q3	99.72	3.75	101.7	Buyer-sourced	PASS
AX-2026-041377	Ipamorelin	QYB-2605-H3558	Nordanalyt	2026-Q3	99.93	4.35	—	Buyer-sourced	PASS
AX-2026-041427	Retatrutide	QYB-2604-B4920	PeptideMeter	2026-Q3	97.93	2.45	101.7	Buyer-sourced	PASS
AX-2026-041428	Retatrutide	QYB-2604-B4920	Janoshik	2026-Q3	98.35	3.20	—	Laboratory-retained	PASS
AX-2026-041473	PT-141 (Bremelanotide)	QYB-2607-L4875	PeptideMeter	2026-Q3	99.58	3.74	94.4	Buyer-sourced	PASS
AX-2026-041472	PT-141 (Bremelanotide)	QYB-2607-L4875	PeptideMeter	2026-Q3	99.93	3.94	—	Buyer-sourced	PASS
AX-2026-041431	Retatrutide	QYB-2604-B4920	Janoshik	2026-Q3	98.63	2.32	94.2	Buyer-sourced	PASS
AX-2026-041432	Retatrutide	QYB-2604-B4920	Janoshik	2026-Q3	98.46	2.14	93.3	Buyer-sourced	PASS